What is claimed is:

1. Use of paliperidone palmitate in the manufacture of a medicament for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar disorder in a patient in need thereof who has been administered a first dose of a paliperidone palmitate extended-release injectable suspension, wherein the use comprises a second dose of the paliperidone palmitate extended-release injectable suspension to be administered to a deltoid or gluteal muscle of the patient up to two weeks before or three weeks after a time that is six months after administration of the first dose, wherein there is no intervening dose of paliperidone palmitate between the first dose and the second dose.

2. The use of claim 1, wherein the second dose is to be administered to the gluteal muscle.

3. The use of claim 1 or claim 2, wherein the patient has a steady state paliperidone plasma concentration at the time of the first dose.

4. The use of any one of the preceding claims, wherein the patient is in need of treatment for schizophrenia.

5. The use of any one of the preceding claims, wherein the first dose comprises about 1092 mg of paliperidone palmitate or about 1560 mg of paliperidone palmitate.

6. The use of any one of the preceding claims, wherein the second dose comprises about 1092 mg of paliperidone palmitate or about 1560 mg of paliperidone palmitate.

7. The use of any one of the preceding claims, wherein the first dose and the second dose each comprise about 1092 mg paliperidone palmitate.

8. The use of any one of claims 1-6, wherein the first dose and the second dose each comprise about 1560 mg paliperidone palmitate.

9. The use of any one of the preceding claims, wherein the plasma concentration of paliperidone in the patient is about 5 to about 50 ng/mL at the time of the second dose.

10. The use of claim 9, wherein when the first dose comprises 1092 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient is about 5 to about 30 ng/mL at the time of the second dose.

11. The use of claim 9, wherein when the first dose comprises 1560 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient is about 9 to about 40 ng/mL at the time of the second dose.

12. The use of any one of the preceding claims, wherein the plasma concentration of paliperidone achieves a peak of about 10 to about 150 ng/mL after administration of the second dose.

13. The use of claim 12, wherein when the first dose is 1092 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient achieves a peak of about 10 to about 125 ng/mL after administration of the second dose.

14. The use of claim 12, wherein when the first dose is 1560 mg paliperidone palmitate, the plasma concentration of paliperidone in the patient achieves a peak of about 35 to about 145 ng/mL after administration of the second dose.

15. The use of any one of the preceding claims, wherein the paliperidone palmitate extended-release injectable suspension comprises:

about 280 mg/mL to about 350 mg/mL of the paliperidone palmitate;
about 8 mg/mL to about 12 mg/mL of a wetting agent;
one or more buffering agents;
about 65 mg/mL to about 85 mg/mL of a suspending agent; and
water q.s. ad 100%.

16. The use of claim 15, wherein the suspension is from about pH 6.0 to about pH 8.0.

17. The use of claim 15 or claim 16, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

18. The use of claim 15, wherein the paliperidone palmitate extended-release injectable suspension comprises:

about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20; and
about 75 mg/mL of polyethylene glycol 4000.

19. Paliperidone palmitate for use in therapy.